Home › Cardiomyopathy › NCT07738107

ATR 1072 in Participants With PRKAG2 Syndrome

A Phase 1/2, Open-Label Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous ATR 1072 for the Treatment of PRKAG2 Syndrome

Who can join

Ages 18 to 65 · All sexes

Inclusion Criteria:

1. Adults 18 to 65 years of age.
2. Pathogenic, likely pathogenic, or variant of uncertain significance (VUS) in PRKAG2 confirmed by genetic testing.
3. Clinical manifestations consistent with PRKAG2 Syndrome.
4. Able and willing to comply with study procedures.
5. Able and willing to undergo endomyocardial biopsy procedures (Part A)

Exclusion Criteria:

1. Pregnancy or breastfeeding.
2. Significant hepatic, renal, hematologic, or cardiovascular abnormalities that may increase study risk.
3. NYHA Class IV heart failure or left ventricular ejection fraction \<45%.
4. Recent clinically significant cardiovascular events or procedures.
5. Prior treatment with prohibited investigational therapies or oligonucleotide therapies within protocol-defined washout periods.
6. Any condition that, in the investigator's

About the study

ATR 1072 is an investigational medicine being studied in adults with PRKAG2 Syndrome. This study will evaluate the safety of ATR 1072 and how the body processes the drug. Researchers will also assess how ATR 1072 affects PRKAG2 activity and measures of heart disease.

What is being tested

• ATR 1072 (drug)

Sponsor: Atrium Therapeutics · Participants: 37 · Started: Sep 14, 2026

Contact the study team

• Patient Recruitment Coordinator · Phone: 283-227-6543

Official record on ClinicalTrials.gov — NCT07738107

Locations in the U.S.

Conditions

• Cardiomyopathy
• Hypertrophy
• Glycogen Storage Disease

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.